Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
03
11
2021
accepted:
10
03
2022
pubmed:
12
5
2022
medline:
21
9
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
The impact of ABO incompatibility on the outcome of hematopoietic stem cell transplantation (HSCT) is still debated. We report the results of a prospective, single-center study evaluating the impact of ABO mismatch on the development of immediate and late immuno-hematological complications, and the efficacy of the protocol used at the "Sapienza" University (Rome, Italy) to manage ABO incompatibility in patients undergoing HSCT. From January 2013 to December 2016, we prospectively analyzed all patients undergoing HSCT. Graft manipulation or desensitization strategies were used according to ABO incompatibility, donor sex and donor transfusion history. Red blood cell and platelet transfusions were given based on immunohematological features. From January 2013 to December 2016, 104 consecutive patients underwent HSCT from a matched related donor (29.81%), matched unrelated donor (53.58%), cord blood (1.9%) or haploidentical donor (14.42%). Forty-nine patients (47%) were ABO-identical and 55 (53%) ABO-incompatible (23 major, 25 minor, 7 bidirectional). Donor engraftment, graft failure or other complications did not differ between ABO compatible or incompatible patients. ABO incompatibility did not show a significant impact on graft-versus-host disease, overall survival or disease-free survival. Factors associated with the need for prolonged red blood cell support were ABO incompatibility (p=0.0395), HLA disparity between donor and recipient (p=0.004) and the onset of hemorrhagic cystitis (p=0.015). In multivariate analysis HLA disparity was the only statistically significant condition (p=0.004). ABO incompatibility does not represent a barrier to allogeneic HSCT. It is, however, associated with prolonged transfusion requirements. Close immunohematological monitoring, as a shared standard procedure, allows appropriate transfusion support to be provided and limits post-HSCT immuno-hematological complications.
Sections du résumé
BACKGROUND
The impact of ABO incompatibility on the outcome of hematopoietic stem cell transplantation (HSCT) is still debated. We report the results of a prospective, single-center study evaluating the impact of ABO mismatch on the development of immediate and late immuno-hematological complications, and the efficacy of the protocol used at the "Sapienza" University (Rome, Italy) to manage ABO incompatibility in patients undergoing HSCT.
MATERIALS AND METHODS
From January 2013 to December 2016, we prospectively analyzed all patients undergoing HSCT. Graft manipulation or desensitization strategies were used according to ABO incompatibility, donor sex and donor transfusion history. Red blood cell and platelet transfusions were given based on immunohematological features.
RESULTS
From January 2013 to December 2016, 104 consecutive patients underwent HSCT from a matched related donor (29.81%), matched unrelated donor (53.58%), cord blood (1.9%) or haploidentical donor (14.42%). Forty-nine patients (47%) were ABO-identical and 55 (53%) ABO-incompatible (23 major, 25 minor, 7 bidirectional). Donor engraftment, graft failure or other complications did not differ between ABO compatible or incompatible patients. ABO incompatibility did not show a significant impact on graft-versus-host disease, overall survival or disease-free survival. Factors associated with the need for prolonged red blood cell support were ABO incompatibility (p=0.0395), HLA disparity between donor and recipient (p=0.004) and the onset of hemorrhagic cystitis (p=0.015). In multivariate analysis HLA disparity was the only statistically significant condition (p=0.004).
DISCUSSION
ABO incompatibility does not represent a barrier to allogeneic HSCT. It is, however, associated with prolonged transfusion requirements. Close immunohematological monitoring, as a shared standard procedure, allows appropriate transfusion support to be provided and limits post-HSCT immuno-hematological complications.
Identifiants
pubmed: 35543676
pii: 2022.0289-21
doi: 10.2450/2022.0289-21
pmc: PMC9480964
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
404-413Références
Bone Marrow Transplant. 2004 Aug;34(4):321-9
pubmed: 15235580
Leukemia. 1999 Dec;13(12):2059, 2060-9
pubmed: 10602430
Transfus Apher Sci. 2020 Oct;59(5):102949
pubmed: 32994126
Asian J Transfus Sci. 2015 Jul-Dec;9(2):181-4
pubmed: 26420941
Am J Obstet Gynecol. 2020 Jul;223(1):119.e1-119.e10
pubmed: 31978433
Bone Marrow Transplant. 2001 Aug;28(4):315-21
pubmed: 11571501
Bone Marrow Transplant. 2019 Oct;54(10):1676-1685
pubmed: 30867557
Haematologica. 2008 Nov;93(11):1605-7
pubmed: 18978296
Transfusion. 2000 May;40(5):543-50
pubmed: 10827256
Blood. 1999 Jun 15;93(12):4425-35
pubmed: 10361141
Transfusion. 1999 Aug;39(8):824-7
pubmed: 10504116
Am J Hematol. 2017 Aug;92(8):789-796
pubmed: 28439910
Br J Haematol. 2015 Sep;170(5):597-614
pubmed: 25921271
Transpl Immunol. 2005 Aug;14(3-4):159-69
pubmed: 15982558
Transfus Med. 2001 Aug;11(4):325-42
pubmed: 11532188
Haematologica. 2007 Aug;92(8):1051-8
pubmed: 17640857
Haematologica. 2008 Nov;93(11):1686-93
pubmed: 18835834
Oncotarget. 2017 Dec 15;9(3):3379-3393
pubmed: 29423053
Vox Sang. 2012 Oct;103(3):231-59
pubmed: 22519920
Bone Marrow Transplant. 2012 Oct;47(10):1287-93
pubmed: 22327127
Transfus Med Hemother. 2016 Jan;43(1):3-12
pubmed: 27022317
Biol Blood Marrow Transplant. 2015 Apr;21(4):589-603
pubmed: 25639770
Transfus Apher Sci. 2021 Feb;60(1):102965
pubmed: 33127310
Bone Marrow Transplant. 2013 Sep;48(9):1161-7
pubmed: 23584439
Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6
pubmed: 25262883
Biol Blood Marrow Transplant. 2013 Aug;19(8):1152-8
pubmed: 23571461
N Engl J Med. 1998 Mar 19;338(12):798-803
pubmed: 9504940
Transfus Apher Sci. 2020 Feb;59(1):102597
pubmed: 31311753
Bone Marrow Transplant. 2003 Nov;32(10):1015-9
pubmed: 14595389
Best Pract Res Clin Haematol. 2008 Jun;21(2):251-7
pubmed: 18503990
Biol Blood Marrow Transplant. 2014 Feb;20(2):264-71
pubmed: 24274982
Transfus Clin Biol. 2020 Aug;27(3):115-121
pubmed: 32659269
Transfus Apher Sci. 2018 Apr;57(2):163-167
pubmed: 29724627
Transfus Med Hemother. 2019 Oct;46(5):356-369
pubmed: 31832061
Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13
pubmed: 16338623
Transfus Med. 2020 Aug;30(4):317-323
pubmed: 32484285
N Engl J Med. 1986 Mar 20;314(12):729-35
pubmed: 3513012
Biol Blood Marrow Transplant. 2007 Feb;13(2):172-82
pubmed: 17241923
Biol Blood Marrow Transplant. 2013 Dec;19(12):1760-1
pubmed: 24125949